gdc

Lung Cancer

Early Adjuvant Treatment with Tagrisso Improves Outcomes in Patients with Non–Small-Cell Lung Cancer and EGFR Mutations
Lung Cancer
Treatment with the targeted drug Tagrisso (osimertinib) as an adjuvant therapy (used in addition to primary therapy, such as surgery or chemotherapy) significantly reduces disease recurrence in patients with localized non–small-cell lung cancer (NSCLC) and an EGFR gene mutation (alteration).
Zepzelca, New Drug Approved for Metastatic  Small-Cell Lung Cancer, Has Fewer Side Effects  than Topotecan Chemotherapy
Lung Cancer
Zepzelca (lurbinectedin), a recently approved drug for patients with metastatic (spreading) small-cell lung cancer, may be even safer than expected, according to data from 2 studies presented at the 2020 ASCO annual meeting.
Tecentriq Improves Patient-Reported Outcomes in Advanced Non–Small-Cell Lung Cancer
Lung Cancer
Patients with metastatic (spreading to other parts of the body) non–small-cell lung cancer who received the drug Tecentriq (atezolizumab) as a first-line therapy had improvements in physical functioning, without worsening of their lung cancer–related symptoms, compared with patients who received chemotherapy.
Imfinzi plus Chemotherapy a New First-Line  Option for Patients with Extensive-Stage Small-Cell Lung Cancer
Lung Cancer
Patients with extensive-stage small-cell lung cancer, a rare type of lung cancer, now have a new first-line treatment option with Imfinzi (durvalumab), a PD-L1 inhibitor, in combination with chemotherapy, according to new results presented at the 2020 ASCO annual meeting. This new combination has been shown to improve survival for these patients, who do not have many treatment options and whose prognosis (survival outlook) is less than 5 years.
Immunotherapy plus Chemotherapy a New Standard of Care for Patients with Extensive-Stage Small-Cell Lung Cancer
Lung Cancer
Patients with a type of lung cancer called extensive-stage small-cell lung cancer now have a new first-line treatment option with immunotherapy in combination with chemotherapy. This new combination has shown to improve survival for these patients, who don’t have many treatment options and whose prognosis is less than 5 years.
The Patient Journey in Non–Small-Cell Lung Cancer: An Overview
Lung Cancer

In this last part of the series, we examine the full patient journey, from diagnosis through treatment, and provide a list of questions for patients to ask their doctors for more information.

Biomarker Testing in Non–Small-Cell Lung Cancer: A Guide for Patients
BiomarkersLung Cancer

Non–small-cell lung cancer, or NSCLC, is the most common form of lung cancer, accounting for about 80% to 85% of all lung cancer cases in the United States.

Biomarkers in Lung Cancer: What Are They and Why Do They Matter?
BiomarkersGenetics & CancerLung Cancer
Patients with advanced lung cancer should be tested for the 5 most common biomarkers so they may receive the best treatment options for their disease.
Treatment of Non–Small-Cell Lung Cancer: A Guide for Patients
Lung Cancer
In the second article of this 4-part series, the authors present an overview of the current treatment landscape for NSCLC, including a description of the most often used treatments and common questions that patients can ask their providers.
Updated Joint Statement on Coronavirus (COVID-19) from Lung Cancer Groups
COVID-19Lung Cancer
LUNGevity and 4 other lung cancer organizations have provided information on the new coronavirus for people with lung cancer and other patients with cancer. This update also provides reliable sources of information for patients.
Page 1 of 8
Results 1 - 10 of 72

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.

Country